Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10200153 | 0.92 | HTR2A (0.33) | DGAT1TRPV3 | |
| Trifluoroacetic Acid SCHEMBL2111857 | 0.86 | HRH4 (0.45) | HRH4HRH3KDM4E | |
| Trifluoroacetic Acid SCHEMBL2110573 | 0.86 | HRH4 (0.41) | HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL2108735 | 0.85 | HRH4 (0.40) | HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL2110806 | 0.85 | PARP1 (0.39) | HRH4HRH3DGAT1 | |
| Trifluoroacetic Acid SCHEMBL2111758 | 0.83 | USP30 (0.39) | DGAT1 | |
| Trifluoroacetic Acid SCHEMBL2111487 | 0.82 | CHRNA7 (0.36) | HRH4HRH3KDM4EDPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL2111885 | 0.82 | CHRNA7 (0.36) | HRH4HRH3SSTR4 | |
| Trifluoroacetic Acid SCHEMBL2110730 | 0.82 | POLB (0.43) | HRH4HRH3SSTR4KDM4E | |
| Trifluoroacetic Acid SCHEMBL2110618 | 0.82 | MCHR1 (0.40) | HRH4HRH3DGAT1DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
| US-9079907-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| EP-2018863-B9 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2015-02-18 | — | — | EP | disclosed |
| EP-2018863-B1 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-2742936-A1 | Fused heterocyclic compound and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-06-18 | — | — | EP | disclosed |
| EP-2727585-A1 | In-vivo screening method | Takeda Pharmaceutical Company Limited (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20120165312-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SHIRAI JUNYA (JP) | 2012-06-28 | — | — | US | disclosed |
| US-8158617-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-05-21 | — | — | US | disclosed |
| EP-2018863-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165312-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | HRH4 172/4885HRH3 462/4885DGAT1 4315/4885 |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | HTR2C, HTR3C, HTR3B | HRH4 172/4885HRH3 462/4885DGAT1 4315/4885 |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | HRH4 172/4885HRH3 462/4885DGAT1 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.